Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.72 |
| ▸ | FPR2 | P25090 | 4/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4901645 | 0.94 | CNR1 (0.65) | CNR1FPR2HTTKMT2AMEN1 | |
| SCHEMBL4637247 | 0.89 | CNR1 (0.57) | CNR1FPR2HTTKMT2AMEN1 | |
| SCHEMBL4637423 | 0.87 | FPR2 (0.75) | CNR1FPR2HTTKMT2AMEN1 | |
| SCHEMBL4637371 | 0.86 | CNR1 (0.69) | CNR1FPR2HTTKMT2AMEN1 | |
| SCHEMBL4901257 | 0.86 | CNR1 (0.60) | CNR1HTTKMT2AMEN1POLB | |
| SCHEMBL4637254 | 0.85 | CNR1 (0.72) | CNR1FPR2HTTKMT2AMEN1 | |
| SCHEMBL4901135 | 0.85 | CA2 (0.64) | CNR1FPR2KMT2AROCK2 | |
| SCHEMBL29615105 | 0.84 | CNR1 (1.00) | CNR1FPR2HTTKMT2AMEN1 | |
| SCHEMBL22834230 | 0.84 | CNR1 (1.00) | CNR1FPR2HTTKMT2AMEN1 | |
| SCHEMBL4637704 | 0.83 | CNR1 (0.71) | CNR1HTTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1807390-A4 | ARYLALKYL UREAS AS CB1 ANTAGONISTS | NEUROGEN CORP (US) | 2008-07-02 | — | — | EP | claimed |
| US-20080009477-A1 | Arylalkyl Ureas As Cb1 Antagonists | NEUROGEN CORPORATION (US) | 2008-01-10 | — | — | US | claimed |
| EP-1807390-A2 | ARYLALKYL UREAS AS CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2007-07-18 | — | — | EP | claimed |
| WO-2006052542-A2 | ARYLALKYL UREAS AS CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2006-05-18 | — | — | WO | claimed |
| US-20080009477-A1 | Arylalkyl Ureas As Cb1 Antagonists | NEUROGEN CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080009477-A1 | Arylalkyl Ureas As Cb1 Antagonists | NEUROGEN CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080009477-A1 | Arylalkyl Ureas As Cb1 Antagonists | NEUROGEN CORPORATION (US) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009477-A1 | Arylalkyl Ureas As Cb1 Antagonists | CNR1, CNR2, GPR119 | CNR1 1/4885FPR2 1195/4885HTT 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.